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Knowledge discovery for the treatment of bacteria affecting the
liver
Pınar YILDIRIM1, Kağan ÇEKEN2, Osman SAKA3

Aim: Biomedical information is buried in millions of published articles, and so it is necessary to use text mining
techniques to skim published articles for relevant information. In this study, we used biomedical text mining techniques
to introduce a liver bacterial infection knowledge-acquisition information system.
Materials and methods: Bacteria names were selected from Medline MeSH data and it was searched to identify the
most frequent bacteria associated with the liver using a text mining system and time based analyses were used to show
the evolution of treatments.
Results: Liver infections constitute a major threat to public health, and our study shows that there is a need for better
drugs.
Conclusion: Both pharmaceutical industry and healthcare providers are encouraged to investigate challenges related
with major liver infections and create strategies to develop new drugs.
Key words: Biomedical text mining, knowledge discovery, bacteria, liver

Karaciğeri etkileyen bakterilerin tedavisi için bilgi keşfi
Amaç: Biyomedikal bilgiler yayınlanmış milyonlarca makalede gömülüdürler ve bu bilgileri sorgulamak için metin
madenciliği yöntemlerinden yararlanılabilir. Biz bu çalışmada, karaciğer bakteriyel enfeksiyonlarına ait bilgi keşfi
yapmak amacıyla ile metin madenciliği yöntemlerini kullandık.
Yöntem ve gereç: Bakteri isimleri Medline MeSH data’dan alınmış ve Medline karaciğerle ilişkili en yüksek frekanslı
bakterileri bulmak için taranmıştır. Bakteriler seçildikten sonra, herbir bakteri için ilişkili makaleler PubMed’den
taranmış, metin madenciliği yöntemleri ve tedavilerin zamana bağlı değişimlerini gösteren analizler kullanılarak ilişkili
tedaviler belirlenmiştir.
Bulgular: Karaciğer enfeksiyonları toplum sağlığı için önemli bir tehlike oluşturmaktadırlar ve bizim çalışmamız daha
iyi ilaçlara ihtiyaç olduğunu göstermiştir.
Sonuç: Hem ilaç endüstrisi hem de sağlık hizmeti sağlayıcıları önemli karaciğer enfeksiyonlarındaki zorlukları
araştırmak ve yeni ilaçlar geliştirmek için stratejiler yaratmak için teşvik edilmelidirler.
Anahtar sözcükler: Biyomedikal metin madenciliği, bilgi keşfi, bakteriler, karaciğer
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Introduction
The biomedical literature, such as Medline articles,
is a rich resource for discovering and keeping up with
medical knowledge. For example, information with
regard to which drugs are used with a particular
disease or changes in drug usage over time is valuable
but unfortunately buried in thousands of articles (1).
Biomedical text mining techniques play an important
role in acquiring knowledge from these articles and
they have been applied to numerous studies so far (1).
Bacterial infections can lead to serious life
threatening complications and death (2). Bacteria are
especially harmful on the liver, which supports almost
every organ and is thus vital for survival. Because of
its strategic location and multidimensional functions,
the liver is also prone to many diseases. In this study,
we developed a knowledge discovery method on the
treatment of bacteria affecting the liver and we hope
that our study provides valuable information to all
scientists and experts working on bacteria affecting
the efficiency of the liver’s mechanism.
We think that our study will also make substantial
contributions in the area of medical research. It helps
physicians to get the facts embedded in medical
articles and to interpret them in order to build

Medline

Selection of
bacteria

up new medical knowledge. Using our method,
pharmaceutical researchers and antibacterial drug
designers can backtrack and evaluate drug usage
against harmful liver bacteria and develop new
effective strategies providing better treatment efficacy.
Materials and methods
In this study, named entity recognition and
time based analysis were used to analyse Medline
articles. The following steps were applied to extract
information about the treatment of harmful liver
bacteria (Figure 1):
• Searching Medline articles to find bacteria
associated with liver diseases most frequently
• Selecting top ranked bacteria
• Collecting articles for each bacterium from
Medline for specific time periods
• Extracting drugs from the published articles
• Normalisation of names of the drugs to obtain
drug search standardisation
• Calculating drugs’ frequencies and showing
differences in liver drug discovery during different
time periods

Medline

Time based
selection of articles
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Line plots
for drugs
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Figure 1. Summary of the research procedure followed in this study.
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Bacteria names were selected from MeSH data in
the National Library of Medicine (NLM) and Medline
was searched to find bacteria that are associated with
the liver most frequently. Four bacteria that were
encountered in the highest number of articles with
the liver in Medline were selected, namely, Salmonella
typhimurium, Staphylococcus aureus, Mycobacterium
tuberculosis, and Helicobacter pylori.
Medline is a collection of biomedical documents
and administered by the National Center for
Biotechnology Information (NCBI) of the United
States National Library of Medicine (NLM) (3).
The documents are available on PubMed website.
PubMed is a service of the National Library of
Medicine and includes over 18 million bibliographic
citations from Medline and other life science journals
for biomedical articles dating back to the 1950s. Full
texts of the articles are not stored; rather, links to
providers’ sites are provided (4). These links lead to
full-text versions of the articles.
Medline abstracts are in XML format and they
contain logical markup to organise meta-information.
For example, the XML structure of Medline abstracts
include meta-information attached to the original
document, such as the name of the journal, author
list, affiliations, and publication dates as well as
annotations inserted by the NLM, such as creation
date of the Medline entry and list of chemicals
associated with the document, as well as related
MeSH headings (5).

After selecting the bacteria, we provided a drug
time based analysis for each bacterium in addition
to relevant articles, collected from PubMed, and
specific drug usage time periods (e.g., 1970-1980,
1980-1990, 1990-2000, and 2000-2009). PubMed
offers many search options for users. For example,
in order to find articles published in the period of
1970-1980 and relevant to S. typhimurium and the
liver, a researcher can use the time range option by
selecting the “1970-1980” date range. Table 1 shows
the obtained total number of articles for the selected
bacteria. The following query was used for finding
published articles for a considered time period. This
query was modified for other time periods to collect
time specific articles.
“Salmonella
typhimurium
“[All
Fields]
AND “liver”[All Fields] AND (“1970”[EDAT]:
“1980”[EDAT])
After retrieving the articles in specific time
periods, drug names were found by using a drug
filter server that tags drug names from Drugbank
(6). The Drugbank database is a bioinformatics
and cheminformatics resource that combines
detailed drug (i.e. chemical, pharmacological, and
pharmaceutical) data with comprehensive drug target
(i.e. sequence, structure, and pathway) information
(7).

Table 1. Number of articles for the bacteria selected.
Time Periods
Bacteria

1970-1980

1980-1990

1990-2000

2000-2009

Total

Number of Articles
Salmonella typhimurium

668

1710

1063

584

4025

Staphylococcus aureus

89

291

304

335

1019

Mycobacterium tuberculosis

174

129

318

350

971

0

8

186

440

634

Helicobacter pylori
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A text mining solution, known as the filter server,
developed by Rebholz Group at the EBI (European
Bioinformatics Institute) was used to extract drug
names from Medline articles. The architecture of the
biomedical text mining system in EBI is based on
regular expressions and provides a framework for
the extraction of facts from the biomedical literature.
The Monq java is the java class library that binds
regular expressions to actions that are automatically
executed whenever a match occurs in the text stream
being processed. In the case of a match, the associated
action can modify the stream or leave it unchanged.
Commonly, XML tags are used to mark named entity
and other regions of interest in the text. Several
thousand regular expression/action pairs can be
combined into one machinery, called a Deterministic
Finite Automation (DFA), and can be used in parallel
with different computer applications (4,5).
In EBI architecture, there are some filter server
solutions and each filter server specialises in
recognising the vocabulary of a particular terminology
and performing specialised actions depending on the
input it receives. A filter server annotates streams of
text. The server runs its embedded software on the
incoming text to recognise and tag the terminology
with XML tags (5). In this study, after using the
drug filter server, which tags drug names taken from
the Drugbank database, all drugs in the articles are
annotated in XML. At the next step, frequencies of
drugs were automatically calculated for each time

period. The frequency of a drug provides the number
of times a drug appears in the selected articles. A
software program that we developed in Java was
used to find the frequencies. In addition, drugs’
therapy classes were searched in Drugbank to find
their categories. After finding categories of all drugs,
antibacterial drugs, which are the main class of
treatment for bacteria, were selected for time based
analysis. Since the number of articles varies in each
time period, the frequencies of drugs were divided
by the number of articles to get the frequencies.
Minitab statistical software was used to create line
plots for each bacterium and the differences between
frequencies are presented in these plots.
Line plots provide drug time analysis for
clinicians to identify drug usage over time and to
compare drugs according to their frequencies. Drugs
have some variations, such as synonyms and brand
names. For example, theophyllin is a synonym of
theophylline. On the other hand, Serax is a brand
name of oxazepam. Drugbank was searched for each
drug, for synonyms and brand names. Drugbank is
one of the biggest resources for drugs and currently
contains >4100 drug entries, corresponding to
>12,000 different trade names and synonyms (6,7).
After finding the variations, these names were
manually normalised to one specific name. Table 2
shows drug name variations, normalised names, and
Drugbank ID, which identifies uniquely each drug in
the Drugbank database.

Table 2. Normalised names of some drugs used against bacteria.

Drug Name Variations

870

Normalised Names

Drugbank ID

Theophyllinse, Theophyllin

Theophylline

DB00277

Erythromycin, Erythrocin Stearate

Erythromycin

DB00199

Ampicillin, Polycillin, Principen

Ampicillin

DB00415

Zidovudine, Retrovir

Zidovudine

DB00495
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Salmonella typhimurium
Infections with nontyphoidal Salmonella have
increased during the last 3-4 decades. Although a
decrease in infections has been reported over the
last decade, Salmonella infections continue to be
a major public health concern in many countries
and the resistance to antimicrobial drugs appear to
pose a particular health risk. In the 1990s, resistance
against the following drugs was reported: ampicillin,
chloramphenicol, streptomycin, sulphonamides,
and tetracycline (8,9). Threlfall et al. investigated the
changes in antimicrobial resistance in S. enteritidis
and S. typhimurium from human infection in England
and Wales in 2000, 2002, and 2004 and reported that
the incidence of resistance to nalidixic acid, coupled
with decreased susceptibility to ciprofloxacin,
has more than doubled between 2000 and 2004.
Resistance to nalidixic acid and ciprofloxacin has
changed from 43% in 2000 to 76% in 2004. The
occurrence of resistance to ampicillin increased
from 5% in 2000 to 8% in 2004, but resistance to
tetracyclines and trimethoprim changed very little
over the 5-year period (10).
Chen et al. analysed the trend of drug resistance
of Salmonella typhimurium in Taiwan in 1991-2001.
Their study showed that the drug resistance rate for a
single drug was the highest for streptomycin at 84.2%,
followed by tetracycline at 82.5%, chloramphenicol
at 71.9%, ampicillin at 70.2%, and nalidixic acid at
18.4%. Changes in drug resistance of Salmonella
typhimurium in recent years were studied using new
generation antibiotics, such as ciprofloxacin and
ceftriaxone. According to their results, ciprofloxacin
of the floronquinolones group showed 3.8% drug
resistance (9).
Figure 2 shows the line plot of antibacterial drugs
for Salmonella typhimurium. According to the figure,
the frequencies of ampicillin and tetracycline have
decreased after the 1980-1990 time period. It also
shows that resistance to these drugs was seen in these
time periods. However, in the 1990-2000 time period,
resistance to tetracycline increased again. Gentamicin
and sulphonamides have also decreasing frequencies
after 1990-2000. Surprisingly, norfloxacin has an
increasing frequency in the 1990s.

Norfloxacin has been proved to be a very broad
spectrum anti-bacterial drug and it is one of the new
4-quinolone anti-bacterial agents introduced in 1984
in the world market. Subsequent to norfloxacin, 4
more new quinolone compounds also have come
onto the market. Still norfloxacin and its successor
ciprofloxacin are able to hold their own market in
their clinical use as popular agents for urinary tract
infections (11).
Staphylococcus aureus
The first cases of methicillin-resistant
Staphylococcus aureus (MRSA) infections were
reported from the UK in 1961 and MRSA became a
major problem in hospital settings worldwide in the
1980s. Although community-acquired MRSA are
emerging worldwide, vancomycin-resistant S. aureus
remain extremely rare. Up until 2007, 3 vancomycinresistant S. aureus cases were reported from the US
in 2002 and 2004. Linezolid is one of the new active
agents and it is active against MRSA (12,13). Figure
3 shows the line plot of antibacterial drugs for S.
aureus. Despite their resistance, the frequencies of
both methicillin and vancomycin have increased in
all time periods. Ciprofloxacin has a decrease after
1990-2000. Rifampin has been increasing but still
has a low frequency. Furthermore, linezolid has been
seen after the 1990-2000 time period and it has an
increasing frequency.
Line plot of antibacterial drugs for Salmonella typhimurium
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Figure 2. Line plot of antibacterial drugs for Salmonella
typhimurium.
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Line plot of antibacterial drugs for Staphylococcus aureus
0.5
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vancomycin

0.35
Frequency

Hsueh et al. summarised data from 1990-2002 in
Taiwan and results showed that primary resistance
ranged from 4.7% to 12% for isoniazid, 0.7% to 5.9%
for rifampin, 1% to 6% for ethambutol, and 4% to
11% for streptomycin (17).

methicillin
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ciprofloxacin
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rifampin
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0.05
0
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infection in AIDS patients in the United States and in
European countries (16).

2000-2009

Time Periods

Figure 3. Line plot of antibacterial drugs for Staphylococcus
aureus.

Figure 4 shows the line plot of antibacterial drugs
that we obtained for M. tuberculosis. According to
the figure, in both 1980-1990 and 1990-2000 time
periods, significant changes have been observed for
some drugs, such as clarithromycin, amikacin, and
rifabutin. In addition, streptomycin and ofloxacin
have also both increases and decreases in these time
periods but these changes are not as sharp as the
others.
Helicobacter pylori

Tuberculosis is caused by Mycobacterium
tuberculosis and kills approximately 2 million people
each year. Due to the intrinsic resistance of M.
tuberculosis to many antibiotics, chemotherapy of
tuberculosis is restricted to a very limited number of
drugs, which have to be used in combination for at
least 6 months (14).
Multidrug-resistant tuberculosis (MDR TB) is a
form of tuberculosis that is resistant to some of the
first-line drugs used for the treatment of the disease.
It is associated both with a higher incidence of
treatment failures and of disease recurrence, as well
as with higher mortality than forms of tuberculosis
sensitive to first-line drugs. Levofloxacin (LFX)
represents one of the few second-line drugs recently
introduced in the therapeutic regimens for MDR TB
(15).
Rifampicin (RFP) was developed as one of the
anti-tuberculosis drugs in 1966 and has been in use
since then. Establishment of combination therapy
using RFP has been contributing to the treatment/
eradication of tuberculosis. A number of rifamycin
derivatives, as post RFPs, have been synthesised/
developed over the years. Chemical modification
of rifamycins has largely been concentrated on the
moiety of naphthalene ring because modification of
the ansa chain moiety reduces the activity. In 1992,
rifabutin was approved as a preventive drug for MAC
872

The discovery that Helicobacter pylori infection is
the main cause of most gastroduodenal diseases has
been a major breakthrough in gastroenterology. It
has dramatically changed the management of these
diseases, which are now considered as infectious
diseases and are treated with antibiotics (18).
Triple therapy, including 2 antibiotics (amoxicillin
and clarithromycin), and a proton pump inhibitor
administered for a week has been recommended as the
treatment of choice at several consensus conferences.
However, this treatment may fail for several reasons,
as reported elsewhere. In fact, the main reason for
Line plot of antibacterial drugs for Mycobacterium tuberculosis
0.12
Amikacin
Streptomycin
0.1

Frequency

Mycobacterium tuberculosis

Clarithromycin
Rifabutin

Ofloxacin

0.08
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0.04
0.02
0
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1990 -2000

2000 -2009
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Figure 4. Line plot of antibacterial drugs for Mycobacterium
tuberculosis.

P. YILDIRIM, K. ÇEKEN, O. SAKA

Line plot of antibacterial drugs for Helicobacter pylori
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Figure 5. Line plot of antibacterial drugs for Helicobacter pylori.

failure was found to be H. pylori resistance to one of
the antibiotics used (that is, clarithromycin). Other
treatments have also been proposed, including
metronidazole, fluoroquinolones, and rifamycins for
which resistance has become an emerging issue (18).
Figure 5 shows the line plot of antibacterial drugs
that we obtained for H. pylori. Except clarithromycin
and dirithromycin, the drugs have increasing
frequencies after the 1990-2000 time period. In
Figure 5, dirithromycin is only seen in the 1990s. It is a
macrolide, like the standard macrolide erythromycin,
as well as clarithromycin and azithromycin. Some
studies showed that it may not offer any unique clinical
advantage over clarithromycin or azithromycin (19).
Discussion
Infections with bacteria are important causes
of morbidity and mortality worldwide. The control
of bacterial disease requires a complex interplay of
activities in the fields of public health, education,
and medical science as well as in politics. There is a
need for treatment, and the search for better drugs
is a perpetual process. Advances in science and
technology have opened up possibilities for new
drugs.
In this study, the analysis of drugs for each
bacterium highlights the frequency of usage decline
and incline of liver drug therapies. Furthermore,

frequencies of liver drugs usage show the most
popular drugs to treat a particular liver bacterium.
According to these analyses, there are no big changes
between time periods in the treatment of bacteria
affecting liver. Despite the large global burden of
bacterial diseases, there has been very little recent
effort by the pharmaceutical industry to develop
agents to treat human bacterial infections (20).
The development of antibacterial drugs faces many
challenges.
Antimicrobial resistance for bacteria threatens
the management of infections, such as pneumonia,
tuberculosis, malaria, and AIDS. During the past 1015 years, antibiotic-resistant organisms have steadily
increased, and now present a threat to disease
management. In the past, resistance could have
been handled by new drugs that are active against
resistant microbes. However, the pharmaceutical
industry has reduced its research efforts in agents
against infections; genomics has not delivered the
anticipated novel therapeutics; new regulatory
requirements have increased costs; antibiotic use in
common infections, e.g. bronchitis and sinusitis is
questioned; and, compared with other drugs, return
on investments is lower for microbials (21).
The protection of proprietary rights and the return
of investments are also important issues for drug
makers. With the long payback period associated
with these indications, costs often are not recovered
when a compound runs off patent and generic
products may be introduced (22).
Regulatory requirements are another major
concern that has a considerable impact on the
length and costs of the drug development process
and, hence, on the ultimate market price of the drug
product. Paradoxically, increasingly demanding
standards favour the larger wealthy companies,
which are those least interested in tropical diseases.
Nevertheless, dossiers do not always undergo the
same level of review worldwide, sometimes because
of limited health budgets, and sometimes owing to
a misconception about the regulatory process (22).
Anti-infective agents differ from many other
drugs in that treatment is normally given for a
short time. By contrast with drugs used to treat
hyperlipidemia, hypertension, and diabetes mellitus,
for example, treatment of infections is rarely life long.
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This short treatment period makes anti-infective
drugs more susceptible to competition, the return
per treatment course is limited, and the need for
industry representatives increases. Marketing efforts
generally continue during the entire life span of these
drugs (21).
Considering all these concerns, from both
clinicians’ and patients’ perspective, antibiotic
resistance is an issue that continues to pose a
significant threat. From the perspective of patients,
headlines such as ‘The revenge of the killer microbes’
only add to their anxiety. As healthcare providers,
they have a responsibility to acknowledge the issue
of increasing resistance and to develop strategies
for combating this continuing challenge to the
management and treatment of infectious diseases
(22).
In connection with this study, Medline abstracts
were analysed. We noticed that although Medline
includes biomedical articles dating back to 1950s,
most articles in the 1950-1960 and 1960-1970 time
periods do not contain abstracts. For example, some
articles published in between 1960 and 1970 were
retrieved from PubMed for analysis of Mycobacterium
tuberculosis, but few drug names were extracted
in these articles and the result does not provide
sufficient information to make a comparison with
other time periods. Therefore, this time period was
removed from the time based analysis.

Conclusion
Biomedical literature provides valuable knowledge
for clinical studies and research. Medical experts
cannot read all the articles in a specific medical
problem and discover hidden connections between
entities. We considered the need of medical doctors
working on bacterial diseases to extract relevant drug
and bacteria information embedded in published
reports. We introduced a time based analysis of
knowledge processing in Medline articles for the
treatment of bacteria affecting liver. Biomedical
text mining techniques were used to get useful facts
embedded in Medline articles. Time based analyses
of bacteria affecting liver-drug obtained in this study
show that biomedical text mining techniques play
an important role in extracting useful information
contained in published articles. Therefore, both
clinicians and researchers can use our proposed timebased comparison to improve treatment efficacy.
This study also reveals that the treatment of bacteria
seems to be stable over the past 4 decades and there
are many challenges in introducing new drugs. The
methodology introduced in this paper presents
a reference model to acquire time based medical
knowledge from the literature.
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